Russell E. Ware, MD, PhD

My Biography & Research My Locations My Education My Publications

Visit the Ware Lab.

Director, Division of Hematology

Institute Co-Director, Cancer and Blood Diseases Institute

Director, Global Health Center

Marjory J. Johnson Chair of Hematology Translational Research

Professor, UC Department of Pediatrics

russell.ware@cchmc.org

513-517-2344

513-803-8941

Board Certified

My Biography & Research

Biography

Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national principal investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.

Dr. Ware has been elected by peers for inclusion in the Best Doctors in America List.

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Hematology, Cancer and Blood Diseases Institute, Cancer Blood Disease Institute, Epidermolysis Bullosa Center, Sickle Cell and Hemoglobin, Hemophilia, Global Health Center, Best Doctors 2017-18

My Locations

Burnet Campus

Burnet Campus

3333 Burnet Ave.

Cincinnati, Ohio 45229-3039

513-636-4200

Directions From

My Education

MD: Duke University School of Medicine, Durham, NC, 1979-83.

Residency: Baylor College of Medicine, Houston, TX, 1983-86.

Fellowship: Duke Medical Center, Durham, NC, 1986-89.

PhD: Duke University School of Medicine, Durham, NC, 1987-91.

Certification: Pediatric Hematology/Oncology.

My Publications

McGann PT, Ferris MG, Ramamurthy U, Santos B, de Oliveira V, Bernardino L, Ware RE. A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol, 88(12); 984-989, 2013. PMID: 24038490

Hankins JS, McCarville MB, Rankine-Mullins R, Reid M, Lobo CL, Moura PG, Ali S, Soares D, Aldred K, Jay D, Aygun B, Bennett J, Kang G, Goldsmith JC, Smeltzer MP, Boyett JM, Ware RE. Prevention of conversion to abnormal TCD velocities with hydroxyurea in children with sickle cell anemia: a Phase III international randomized clinical trial. Am J Hematol 2015 Dec; 90(12):1099-105. PMC4715740

Ware RE, Davis BR, Schultz WH, Brown, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet 2016 Feb; 387 (10019): 661-670. PMID: 26670617

Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob Health 2016 Mar, 4(3): e195-e200. PMID: 26833239

Schaefer BA, Kiyaga C, Howard TA, Ndeezi G, Hernandez AG, Ssewanyana I, Paniagua MC, Ndugwa CM, Aceng JR, Ware RE. Hemoglobin variants identified in the Uganda Sickle Surveillance Study. Blood Advances 2016 Nov, 1: 93-100.

McGann PT, Hernandez AG, Ware RE. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood 2017 Jan 12; 129(2):155-161. PMID: 27821508

Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle Cell Disease. Lancet, 2017 July 16; 390 (10091). PMID: 28159390

Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE,* John CC.* (co-senior authors) Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a randomized controlled trial. Blood, Dec 14, 2017. 130(24):2585-2593. PMID: 29051184

McGann PT, Williams TN, Olupot-Olupot P, Tomlinson GA, Lane A, Stuber S, Howard TA, McElhinney K, Aygun B, Latham T, Santos B, Tshilolo L, Ware RE. Realizing Effectiveness Across Continents with Hydroxyurea: Successful enrollment and baseline characteristics of the multicenter REACH study in sub-Saharan Africa. Am J Hematol, 2018 Aug; 93(4):537-545. PMC5870803